The DreamStation BiPAP AVAPS devices provide advanced respiratory support to lower-weight patient populations. The availability of the devices will help address critical care gaps and supply challenges in the U.S.
“Patient safety is at the heart of everything we do, and expanding access to advanced, reliable care is essential,” said Sam Talya, Business Category Leader, Therapy Platforms, Sleep and Respiratory Care at Philips. “The availability of DreamStation BiPAP AVAPS devices in the US for lower-weight patients supports a limited patient population. It is a signal of our commitment to ensure access to safe, effective respiratory solutions for patients who need them most.”
Devices will be available for purchase only to Philips customers who meet certain distribution control and traceability requirements.
Delivering Meaningful Support for Patients and Customers
Philips is committed to delivering solutions grounded in clinical rigor. The company is also committed to returning to serving patients who rely on its sleep and respiratory therapy devices in the U.S. when it has fully met the requirements of the Philips Respironics Consent Decree, which the company is diligently working to meet.
DreamStation devices with the new silicone sound-abatement foam have been subject to comprehensive testing in accordance with the applicable industry testing standards. Philips is confident these devices will help customers support the needs of their lower-weight patients.
Philips products and solutions are designed to address critical clinical needs in both hospital and home environments. By offering therapy products and technologies that can enhance patient comfort and offer versatility, Philips is helping to expand access to care while empowering clinicians to provide better care to more people.
Source: Philips
